Medicenna Says MDNA2091 Preclinical Data Shows Improved Disease Symptoms in Mouse Models

12:38 PM EDT, 10/26/2026 (MT Newswires) -- Medicenna Therapeutics (MDNA.TO) on Monday reported preclinical data showing that its candidate MDNA2091 improved disease symptoms and demonstrated "potent" suppression of overactive immune-cell activity of CD122, a type of protein. In two aggressive mouse models of acute graft-versus-host disease (aGvHD), treatment with MDNA209 improved disease symptoms and extended median survival by three- to four-fold versus controls, a statement said. The findings were reported in an oral presentation at an Interleukin-2 Therapies Conference in Paris, France, last week. "These results demonstrate potent CD122 blockade with MDNA209 in human immune cells and a substantial survival benefit in two aggressive preclinical models of GvHD, further strengthening the promise of our IL-2 Superkine platform," said Chief Executive Officer Fahar Merchant. Medicenna shares were last seen down CA$0.005 at CA$0.42 on the Toronto Stock Exchange. Price: 0.42, Change: -0.01, Percent Change: -1.18